INFLUENCE OF PENTOBARBITAL ON UPPER AIRWAY RESISTANCE AND COLLABSIBILITY

戊巴比妥对上呼吸道阻力和塌陷性的影响

• 批准号: 7606977
• 负责人: Atul Malhotra
• 金额: $ 2.17万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606977
• 关键词: Airway Resistance; Breathing; Cardiovascular Diseases; Computer Retrieval of Information on Scientific Projects Database; Disease; Dose; Funding; Grant; Institution; Lung; Muscle; Muscle function; Obstructive Sleep Apnea; Patients; Pentobarbital; Pharmaceutical Preparations; Purpose; Research; Research Personnel; Resources; Risk; Sales; Sleep; Sleeplessness; Source; United States Food and Drug Administration; United States National Institutes of Health; falls; sedative

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine how the muscles of the upper airway, the upper airway itself, and the lung respond to low doses of the sedative drug pentobarbital. Pentobarbital is approved by the FDA for sale as a medication against 'insomnia' (patient's dissatisfaction with the quality of sleep). Pentobarbital has been used frequently and safely for decades in patients with insomnia, and recent findings suggest that this drug may also be useful for treatment of patients with a disease called obstructive sleep apnea (OSA). Patients with OSA are not able to breathe normally during sleep, resulting in severe daytime sleepiness and an increased risk of developing cardiovascular diseases. Typically, the muscles that hold open the upper airway, relax in patients with OSA while falling asleep resuting in an upper airway collapse. This causes the patietns to stop breathing and to wake up some seconds later. It has been shown that this brief awakening at the end of an obstructive sleep apnea episode makes it more likely to develop breathing problems in the next several breaths. Pentobarbital may be useful for treatmetn of OSA, because this drug makes patients wake up less easilty and may alsoimprove the function of the muscles that open the airway.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是确定上呼吸道，上呼吸道本身和肺部的肌肉如何应对低剂量的镇静药物五边形。 FDA批准了五叶牙本质的批准，以抗击“失眠”（患者对睡眠质量的不满）。 几十年来，在失眠症患者中，五仅经常被安全地使用，并且最近的发现表明，该药物也可用于治疗称为阻塞性睡眠呼吸暂停（OSA）的疾病患者。 OSA患者在睡眠期间无法正常呼吸，导致白天昏昏欲睡，并增加患心血管疾病的风险。 通常，在上呼吸道塌陷中入睡的同时，在OSA的患者中放松上呼吸道的肌肉，在OSA的患者中放松身心。 这会导致帕特恩斯停止呼吸，并在几秒钟后醒来。 已经表明，在阻塞性睡眠呼吸暂停发作结束时，这种简短的觉醒使在接下来的几次呼吸中更有可能出现呼吸问题。 戊巴比妥可能对OSA的处理可能很有用，因为该药物使患者醒来较低，并且也可能破解了打开气道的肌肉功能。